Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-upNo signs or symptoms of overexpression toxicity, including in one patient with a mild variant predicted to result in residual MeCP2 expressionNeurogene remains on track to provide interim efficacy data from the trial in 4Q:24 NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome, which showed that NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately nine, six and three months post-dosing. These data were presented during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.“We designed NGN-401 to overcome the limitations of conventional gene therapy
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $51.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesBusiness Wire
- Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
NGNE
Earnings
- 5/10/24 - Beat
NGNE
Sec Filings
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- 5/7/24 - Form 8-K
- NGNE's page on the SEC website